Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.
Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
Type:
Grant
Filed:
September 10, 2021
Date of Patent:
June 27, 2023
Assignees:
Valneva Austria GmbH, Dynavax Technologies Corporation
Inventors:
Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen, Jürgen Heindl-Wruss
Abstract: The present invention relates to the prevention and/or treatment of retinal disorders, such as cone dystrophies, cone-rod dystrophies, in particular Achromatopsia.
Type:
Grant
Filed:
January 14, 2019
Date of Patent:
June 20, 2023
Assignee:
UCL BUSINESS LTD.
Inventors:
Robin Ali, Takaaki Matsuki, Alexander Smith, Anastasios Georgiadis
Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
Type:
Grant
Filed:
June 24, 2020
Date of Patent:
June 13, 2023
Assignee:
CureVac SE
Inventors:
Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
Abstract: Immune compositions comprising (i) a respiratory syncytial virus (RSV) G polypeptide, which may be a modified G polypeptide relative to the wild-type counterpart, or a nucleic acid encoding such, and (ii) a solvent and one or more immune regulators, wherein the immune regulator(s) is dissolvable in the solvent. Also provided herein are methods for eliciting anti-RSV immune responses using the immune compositions disclosed herein and methods for producing the immune compositions.
Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
May 30, 2023
Assignees:
The Trustees of the University of Pennsylvania, The Johns Hopkins University, Vanderbilt Univeisily
Inventors:
Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.
Type:
Grant
Filed:
February 25, 2021
Date of Patent:
May 30, 2023
Assignees:
Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
Inventors:
Jian Yan, Kate Broderick, David Weiner, Kar Muthumani, Ami Patel
Abstract: Compositions, methods and kits are provided for treating complement related disorders in a subject with protein in combination having protein fusions of at least two of a CD46 protein, a CD55 protein and a CD59 protein or with a recombinant chimeric protein having at least two of a CD46 protein, a CD55 protein and a CD59 protein or with nucleic acids encoding these proteins. The composition negatively modulates classical and alternative complement pathways thereby treating complement related disorder such as macular degeneration, age-related macular degeneration, diabetic retinopathy, inflammatory bowel disease, thyroiditis, cryoglobulinaemia, fetal loss, organ graft rejection, cancer, etc.
Type:
Grant
Filed:
October 9, 2020
Date of Patent:
May 23, 2023
Assignee:
Trustees of Tufts College
Inventors:
Rajendra Kumar-Singh, Derek Leaderer, Siobhan M. Cashman
Abstract: The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
Type:
Grant
Filed:
September 14, 2020
Date of Patent:
May 23, 2023
Assignee:
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
Abstract: Provided is a method of producing reassortant influenza virus containing an antigenic protein of the first influenza virus strain, the method including the following steps: 1) a step of irradiating the first influenza virus strain with ultraviolet light in such an irradiation dose that the first influenza virus strain has initial infection ability and loses or is reduced in virus growth potential; 2) a step of infecting a host with the first influenza virus strain and the second influenza virus strain; 3) a step of culturing the host infected with the first influenza virus strain and the second influenza virus strain, to obtain culture product; 4) a step of inactivating influenza virus strain having an antigenic protein of the second influenza virus strain in the culture product obtained in the step 3); and 5) a step of collecting reassortant influenza virus after the step 4).
Type:
Grant
Filed:
July 11, 2017
Date of Patent:
April 25, 2023
Assignee:
The Research Foundation for Microbial Diseases of Osaka University
Abstract: Chimeric flaviviruses engineered to contain a reporter gene and chimeric nucleic acid molecules encoding the chimeric flaviviruses are described. The chimeric flaviviruses further include genomic non-coding regions, non-structural proteins, and at least a portion of a capsid (C) protein from West Nile virus (WNV), and premembrane (prM) and envelope (E) proteins from dengue virus (DENV). Diagnostic assays that utilize chimeric West Nile/dengue viruses are further described.
Type:
Grant
Filed:
August 17, 2018
Date of Patent:
April 25, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.
Type:
Grant
Filed:
February 13, 2020
Date of Patent:
March 28, 2023
Assignees:
Virttu Biologics Limited, The University of Sheffield
Inventors:
Joe Conner, Munitta Muthana, Claire Elizabeth Lewis
Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
Type:
Grant
Filed:
October 3, 2017
Date of Patent:
March 14, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong
Abstract: Engineered Influenza polynucleotides, viruses, vaccines, and methods of making and using the same are provided. More specifically, the present inventors have developed replication competent engineered influenza viruses having, for example, a modified segment 4 and/or segment 6 that include at least one additional polynucleotide encoding a heterologous polypeptide.
Type:
Grant
Filed:
July 12, 2017
Date of Patent:
March 7, 2023
Assignee:
Duke University
Inventors:
Nicholas Scott Heaton, Alfred Theodore Harding, Brook Elizabeth Heaton
Abstract: The present disclosure relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present disclosure provides a composition comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
March 7, 2023
Assignees:
VANDERBILT UNIVERSITY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE JOHNS HOPKINS UNIVERSITY
Inventors:
James E. Crowe, Jr., Andrew Flyak, Justin Bailey, Stuart Ray, George Shaw
Abstract: Provided herein are compositions and methods for packaging a recombinant adeno-associated vims (rAAV) particle comprising using inverted terminal repeats (ITRs) and rep genes of different serotypes and/or using chimeric rep genes.
Type:
Grant
Filed:
March 6, 2019
Date of Patent:
March 7, 2023
Assignee:
University of Florida Research Foundation, Incorporated
Inventors:
Mavis Agbandje-McKenna, Mario Mietzsch, Robert McKenna
Abstract: Methods for rapidly confirming production of infectious viral vectors, for use in clinical grade personalized neo-antigen vaccines for subjects in need thereof, are provided.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
February 7, 2023
Assignees:
NantCell, Inc., NantBio, Inc.
Inventors:
Adrian E. Rice, Kayvan Niazi, Frank R. Jones